With 45.03 million shares changed hands, the volume of the stock remained heavier than its average volume of 15.49 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $47.5 whereas the lowest price it dropped to was $44.37. The 52-week range on BMY shows that it touched its highest point at $70.93 and its lowest point at $47.58 during that stretch. It currently has a 1-year price target of $55.00. With its current market cap of 90.60 billion, BMY has annualized dividend of $2.34 while the current yield stands at 5.23%. Beta for the stock currently stands at 0.41.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BMY was down-trending over the past week, with a drop of -7.45%, but this was down by -14.94% over a month. Three-month performance dropped to -9.90% while six-month performance fell -20.35%. The stock lost -36.36% in the past year, while it has lost -12.88% so far this year. A look at the trailing 12-month EPS for BMY yields 3.86 with Next year EPS estimates of 6.98. For the next quarter, that number is 1.70. This implies an EPS growth rate of -92.35% for this year and 1114.07% for next year. EPS is expected to decline by -4.17% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 5.14%.
Float and Shares Shorts:
At present, 2.03 billion BMY shares are outstanding with a float of 2.03 billion shares on hand for trading. On 2024-04-15, short shares totaled 34.36 million, which was 170.00000000000003 higher than short shares on 1710460800. In addition to Dr. Christopher S. Boerner Ph.D. as the firm’s CEO & Chairman, Mr. David V. Elkins serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.78973 of BMY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, BMY reported revenue of $11477000000.0 and operating income of $1903000000.0. The EBITDA in the recently reported quarter was $4148000000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BMY since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
